Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-07-15
DOI
10.3389/fimmu.2021.638678
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Moderate Risk of Hepatitis B Virus Reactivation in HBsAg−/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis
- (2020) Meng Hsuan Kuo et al. Scientific Reports
- Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia
- (2020) Jia Wang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Risk of hepatitis B reactivation is controllable in patients with B‐cell lymphoma receiving anti‐CD19 CAR T cell therapy
- (2020) Wei Liu et al. BRITISH JOURNAL OF HAEMATOLOGY
- Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection
- (2020) Chunmei Yang et al. LEUKEMIA
- Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma
- (2020) Ping Li et al. Frontiers of Medicine
- Different sites of extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor T cell therapy
- (2020) Lili Zhou et al. Frontiers of Medicine
- Humanized anti‐CD19 chimeric antigen receptor‐T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection
- (2020) Rui Cui et al. HEMATOLOGICAL ONCOLOGY
- Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
- (2020) Lu Han et al. Journal for ImmunoTherapy of Cancer
- Safety of CAR T-Cell Therapy in Patients with B-Cell Lymphoma and Chronic Hepatitis B or C Virus Infection
- (2019) Paolo Strati et al. BLOOD
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma
- (2019) Jia Wei et al. Journal for ImmunoTherapy of Cancer
- Hepatitis B virus and risk of non-Hodgkin lymphoma: An updated meta-analysis of 58 studies
- (2018) M. Li et al. JOURNAL OF VIRAL HEPATITIS
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study
- (2015) Shigeru Kusumoto et al. CLINICAL INFECTIOUS DISEASES
- American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
- (2015) Robert P. Perrillo et al. GASTROENTEROLOGY
- Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study
- (2014) Wai-Kay Seto et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis B
- (2013) Yi-Hsiang Huang et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports
- (2010) A. M. Evens et al. ANNALS OF ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now